Ceftazidime-Avibactam Susceptibility Breakpoints against Enterobacteriaceae and Pseudomonas aeruginosa.
Wright W NicholsGregory G StonePaul NewellHelen BroadhurstAngela WardmanMerran MacPhersonKatrina YatesTodd RiccobeneIan A CritchleyShampa DasPublished in: Antimicrobial agents and chemotherapy (2018)
Clinical susceptibility breakpoints against Enterobacteriaceae and Pseudomonas aeruginosa for the ceftazidime-avibactam dosage regimen of 2,000/500 mg every 8 h (q8h) by 2-h intravenous infusion (adjusted for renal function) have been established by the FDA, CLSI, and EUCAST as susceptible (MIC, ≤8 mg/liter) and resistant (MIC, >8 mg/liter). The key supportive data from pharmacokinetic/pharmacodynamic analyses, in vitro surveillance, including molecular understanding of relevant resistance mechanisms, and efficacy in regulatory clinical trials are collated and analyzed here.
Keyphrases
- pseudomonas aeruginosa
- gram negative
- multidrug resistant
- klebsiella pneumoniae
- cystic fibrosis
- acinetobacter baumannii
- biofilm formation
- clinical trial
- public health
- drug resistant
- big data
- transcription factor
- escherichia coli
- randomized controlled trial
- open label
- candida albicans
- data analysis
- double blind
- placebo controlled